new weight loss drug semaglutide Novo Nordisk's weight-loss pill wins FDA approval Demand Rising for 'Bootlegged' Weight-Loss

Lifestyle Gaps That Prevent Weight Loss on GLP-1 Therapy Semaglutide suppresses appetite but does not eliminate the need for intentional nutrition choices

Conclusion: A Promising Future for Combined Aesthetic and Metabolic Treatments The combination of Semaglutide and CO2 Fractional Laser represents a cutting-edge approach to aesthetic medicine, offering patients a comprehensive solution that addresses both metabolic health and skin rejuvenation

Pancreatic enzymes (amylase and lipase) should remain normal on semaglutide unless you have a history of pancreatitis

Regulatory Timeline Context Health Canada continues reviewing the nine pending generic applications following the January 4, 2026 patent expiration